Credit score Suisse Says AbbVie’s Humira Patent Cliff Might Present Momentum to Increase Progress
[ad_1]
-
Credit score Suisse has initiated protection on AbbVie Inc (NYSE: ABBV) with an Outperform score and a worth goal of $170.
-
AbbVie stands on the sting of best-selling Humira’s U.S. lack of exclusivity (LOE) in 2023. Whereas this stays the main target of investor discussions, Credit score Suisse sees it as a catalyst to push the narrative from a worth story to a development story.
-
In line with Credit score Suisse analysts, the administration has put the constructing blocks for development with Skyrizi, Rinvoq, and aesthetics, that are underappreciated.
-
Associated: AbbVie Studies Blended Earnings, Tightens Steerage, Lifts Quarterly Dividend.
-
In contrast to most friends, there’s probably restricted urgency for enterprise growth (BD), on condition that no different significant LOEs are till 2029. Given its robust money era and excessive dividend yield, low valuation is a beautiful entry level as administration executes on returning to development in 2024.
-
Value Motion: ABBV shares are up 1.80% at $154.895 on the final test Friday.
-
Picture Through Firm
Newest Scores for ABBV
|
Date |
Agency |
Motion |
From |
To |
|---|---|---|---|---|
|
Feb 2022 |
UBS |
Downgrades |
Purchase |
Impartial |
|
Feb 2022 |
Mizuho |
Maintains |
Purchase |
|
|
Feb 2022 |
Barclays |
Maintains |
Equal-Weight |
View Extra Analyst Scores for ABBV
View the Newest Analyst Scores
See extra from Benzinga
Do not miss real-time alerts in your shares – be a part of Benzinga Professional free of charge! Attempt the device that may provide help to make investments smarter, quicker, and higher.
© 2022 Benzinga.com. Benzinga doesn’t present funding recommendation. All rights reserved.
Source link